Dorothee Childs presented her work at the EMBL-Wellcome Genome Campus Conference “Target Validation using Genomics and Informatics 2015”, which took place from 8th to 10th December 2015 in Cambridge.
More than 200 people attended this ground-breaking conference. Dorothee gave a talk on “Screening for drug targets in intact cells by thermal proteome profiling”, a project in which she is involved as part of a collaboration between EMBL Heidelberg and GSK’s SME Cellzome, which is also based in Heidelberg.”
Annika Gable has a B.Sc. in Molecular Biotechnology from the University of Heidelberg. She joined the Huber group in December 2015. At EMBL, she is finishing up her M.Sc. in Molecular Biotechnology (major: Bioinformatics) with a thesis on analyzing high-throughput chromatin conformation capture (Hi-C) data.
Junyan has a PhD in Computational Biology and Drug Design from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. His previous research focused on understanding mechanisms of drug response using integrated multi-omics technology and large scale ex-vivo drug testing approaches. In November 2015, he joined the Huber Group as a postdoctoral fellow and is now working on the SOUND project.
Mike joined EMBL in October 2015 as part of the de.NBI project where he is working on the development pipelines, workflows and computational approaches for large scale biological experiments. He has a PhD in computational biology from the University of Cambridge, UK.
In October 15, 2015, Alejandro Reyes successfully defended his PhD thesis titled “Analysis of transcript isoform regulation using high-troughput RNA sequencing” with the distinction “summa cum laude”.
Sascha Dietrich’s project proposal within the health research program “Junior Group in Systems Medicine” of the German Federal Ministry of Education and Research (BMBF) was positively evaluated. This multidisciplinary project, which is intended to have direct clinical impact on patient care in blood cancers, is titled “An integrated systems medicine approach to personalized and targeted therapy in leukaemia and lymphoma”.
In November 2014 two of our PhD students, Felix Klein and Paul Theodor Pyl, successfully defended their theses.